TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7879322

Group type: EXPERIMENTAL
Intervention: Intraurethral administration of prostaglandin E1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intracavernous administration of half the dose of prostaglandin E1
Number of subjects: 0
Study: 2242101

Group type: EXPERIMENTAL
Intervention: Boiled coffee (BC)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Filtered coffee (FC)
Number of subjects: 41
Study: 227069

Group type: EXPERIMENTAL
Intervention: econazole-triamcinolon combination
Number of subjects: 58

Group type: COMPARATOR
Intervention: econazole
Number of subjects: 58
Study: 30958012

Group type: EXPERIMENTAL
Intervention: Motivational Intervention (MI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brief advice (Control)
Number of subjects: 0
Study: 28043669

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning with postconditioning (RIPC with RIPostC)
Number of subjects: 1280

Group type: COMPARATOR
Intervention: Sham (control)
Number of subjects: 1280
Study: 25366707

Group type: EXPERIMENTAL
Intervention: Radiologist adjustments to screen results
Number of subjects: 3318
Study: 24224396

Group type: EXPERIMENTAL
Intervention: CO2 laser fiber
Number of subjects: 45

Group type: COMPARATOR
Intervention: Cold knife
Number of subjects: 45
Study: 21464455

Group type: EXPERIMENTAL
Intervention: VCT at bars
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: VCT at church
Number of subjects: 591

Group type: COMPARATOR
Intervention: VCT at health centre
Number of subjects: 591
Study: 20002082

Group type: EXPERIMENTAL
Intervention: LC15-0444 200 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LC15-0444 400 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LC15-0444 600 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16804951

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PRRs (Proportional Reporting Ratios)
Number of subjects: 0
Study: 14994729

Group type: EXPERIMENTAL
Intervention: Carotid thromboarterectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carotid stenting
Number of subjects: 0
Study: 10807761

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) with 2 mg estradiol + 1 mg norethisterone
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 8923067

Group type: EXPERIMENTAL
Intervention: PCA with dipyrone (initially 2.0 g i.v. and 1.0 g/2 ml i.v. at 4, 8 and 16 h)
Number of subjects: 106

Group type: COMPARATOR
Intervention: PCA with placebo (saline)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 106
Study: 1366330

Group type: EXPERIMENTAL
Intervention: Alginete pills with diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual reduction diet
Number of subjects: 0
Study: 6687341

Group type: EXPERIMENTAL
Intervention: Peer-taught curriculum
Number of subjects: 1081

Group type: EXPERIMENTAL
Intervention: Adult-taught curriculum
Number of subjects: 1081

Group type: COMPARATOR
Intervention: Control school
Number of subjects: 1081
Study: 30578894

Group type: EXPERIMENTAL
Intervention: 12-weeks supervised moderate exercise program
Number of subjects: 34

Group type: COMPARATOR
Intervention: Waitlist, control condition
Number of subjects: 34
Study: 28957833

Group type: EXPERIMENTAL
Intervention: PureMoist
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RevitaLens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clear Care (CC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biotrue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saline Solution (SS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RevitaLens (RL)
Number of subjects: 0
Study: 26396165

Group type: EXPERIMENTAL
Intervention: Sensory dynamic orthosis sleeve
Number of subjects: 21

Group type: COMPARATOR
Intervention: Non-compressive sleeve (placebo)
Number of subjects: 21
Study: 25335348

Group type: EXPERIMENTAL
Intervention: N2 jet cryotherapy once a week for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Topical 0.05% clobetasol proprionate lotion
Number of subjects: 40
Study: 23106924

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interdisciplinary focus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple sites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flexible study design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proactive staff management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protocol implementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timely data tracking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complex multi-site trials
Number of subjects: 0
Study: 20576091

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30‐70 mg/d
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 127
Study: 18584266

Group type: EXPERIMENTAL
Intervention: Discussing a negative personal experience
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Discussing a positive personal experience
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: High hostility individuals
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Support recipients and providers
Number of subjects: 216
Study: 16061764

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (paroxetine hydrochloride or bupropion hydrochloride)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Community Referral
Number of subjects: 267
Study: 11949768

Group type: EXPERIMENTAL
Intervention: Triazolam (0.125 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Temazepam (15 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Temazepam (30 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ethanol (0.5 g/kg) + Triazolam
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ethanol (0.5 g/kg) + Temazepam
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ethanol (0 g/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10349927

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2% via lumbar epidural block
Number of subjects: 28

Group type: COMPARATOR
Intervention: bupivacaine 0.25% (0.7 ml x kg(‐1)) via lumbar epidural block
Number of subjects: 28
Study: 7572122

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine injection (1 mg/kg)
Number of subjects: 30
Study: 2163814

Group type: EXPERIMENTAL
Intervention: Erythromycin for a maximum of 10 weeks
Number of subjects: 1476

Group type: COMPARATOR
Intervention: Placebo for a maximum of 10 weeks
Number of subjects: 1476
Study: 795441

Group type: EXPERIMENTAL
Intervention: Colestipol HCl 10 g twice daily
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Colestipol HCl
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 31640694

Group type: EXPERIMENTAL
Intervention: Performance-Based Financing (PBF) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group (quasi-experimental design)
Number of subjects: 0
Study: 24916207

Group type: EXPERIMENTAL
Intervention: Job aids-focused intervention
Number of subjects: 411

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 411
Study: 22534451

Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention (MBRP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-as-usual (control group)
Number of subjects: 0
Study: 20650587

Group type: EXPERIMENTAL
Intervention: 25-s injection duration
Number of subjects: 116

Group type: COMPARATOR
Intervention: 35-s injection duration
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 116
Study: 18806924

Group type: EXPERIMENTAL
Intervention: Change detection with peripheral faces changing to joy, anger, or disgust during the visual letter task.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Change to disgust as a specific emotion expression change.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implicit change detection during the tasks.
Number of subjects: 0
Study: 22298019

Group type: EXPERIMENTAL
Intervention: Transdermal GTN (0.6 mg/h) for 2 h a day for 6 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral PETN (80 mg) once a day for 6 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 30
Study: 15900289

Group type: EXPERIMENTAL
Intervention: 750 mg AZD3582
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1500 mg AZD3582
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 50 mg rofecoxib
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 500 mg naproxen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12576917

Group type: EXPERIMENTAL
Intervention: Arm A: three 8‐mg doses of ondansetron intravenously at 4‐hour intervals plus dexamethasone 20 mg intravenously from the start of chemotherapy, followed by dexamethasone 5 mg intravenously every 12 hours.
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Arm B: three 8‐mg doses of ondansetron intravenously at 24‐hour intervals plus dexamethasone as in Arm A.
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Complete control of vomiting/nausea for patients without emesis during previous cycles.
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Female patients during chemotherapy cycles.
Number of subjects: 400
Study: 9609084

Group type: EXPERIMENTAL
Intervention: Abciximab treatment
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Abciximab with standard-dose heparin
Number of subjects: 638
Study: 7707848

Group type: EXPERIMENTAL
Intervention: Endorectal advancement flap (group A, n = 34)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Mucosal flap (group B, n = 21)
Number of subjects: 55
Study: 2760974

Group type: EXPERIMENTAL
Intervention: Rice powder electrolyte solution
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Glucose electrolyte solution
Number of subjects: 30
Study: 899804

Group type: EXPERIMENTAL
Intervention: High or low tones without requirement for motor response
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High or low tones with requirement of motor response
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Identical number of high and low tones in random order with requirement of motor response to only 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Only high tones with instruction that both tones will appear in random order and requirement for motor response to one
Number of subjects: 0

Group type: COMPARATOR
Intervention: All series of stimuli
Number of subjects: 0
Study: 12715722

Group type: EXPERIMENTAL
Intervention: Anakinra (recombinant IL-1 receptor antagonist) with or without methotrexate
Number of subjects: 0
Study: 29795141

Group type: EXPERIMENTAL
Intervention: PSA 2.5-4 ng/mL
Number of subjects: 1534

Group type: EXPERIMENTAL
Intervention: PSA 4.1-6 ng/mL
Number of subjects: 1534

Group type: EXPERIMENTAL
Intervention: PSA 6-10 ng/mL
Number of subjects: 1534
Study: 27475817

Group type: EXPERIMENTAL
Intervention: Retromuscular polypropylene mesh
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Double-row plication with Quill technology
Number of subjects: 86

Group type: COMPARATOR
Intervention: Physical training only (control)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: All groups (including both operative groups and control)
Number of subjects: 86
Study: 23713767

Group type: EXPERIMENTAL
Intervention: Oral moxifloxacin 400 mg in fed state
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral moxifloxacin 400 mg in fasted state
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo in fed state
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo in fasted state
Number of subjects: 32
Study: 22573670

Group type: EXPERIMENTAL
Intervention: English words with negative valence (e.g., 'violence')
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: English words with positive and neutral valence (e.g., 'holiday', 'theory')
Number of subjects: 0
Study: 20536509

Group type: EXPERIMENTAL
Intervention: Resistant starch (40 g/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo supplement (0 g/day)
Number of subjects: 20
Study: 18557165

Group type: EXPERIMENTAL
Intervention: Tramadol ER 300 mg
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Tramadol ER 200 mg
Number of subjects: 386

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386
Study: 16307955

Group type: EXPERIMENTAL
Intervention: Sentence production experiment in Odawa language
Number of subjects: 0
Study: 12214263

Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg/Indapamide 0.625 mg
Number of subjects: 500

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 500
Study: 10463514

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 250 mg twice daily
Number of subjects: 263

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate 500/125 mg 3 times daily
Number of subjects: 263
Study: 8527266

Group type: EXPERIMENTAL
Intervention: Metoprolol 50 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Celiprolol 200 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 2562010

Group type: EXPERIMENTAL
Intervention: Fluxum (low molecular weight heparin)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Calcium-heparin
Number of subjects: 88
Study: 853979

Group type: EXPERIMENTAL
Intervention: bivalent iron sulfate (quick release stick capsule preparation)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: trivalent iron citrate complex preparations
Number of subjects: 9

Group type: COMPARATOR
Intervention: ferric iron preparations
Number of subjects: 9
Study: 31687831

Group type: EXPERIMENTAL
Intervention: Helmet NIV (positive end-expiratory pressure ≥ 10 cm H2O, pressure support = 10-15 cm H2O)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Helmet NIV
Number of subjects: 15
Study: 31593855

Group type: EXPERIMENTAL
Intervention: Victim belonging to ingroup
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Victim not belonging to ingroup
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: High trait anxiety with victim not belonging to ingroup
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: High trait anxiety with victim belonging to ingroup
Number of subjects: 202
Study: 29037181

Group type: EXPERIMENTAL
Intervention: Monocryl® (poliglecaprone 25)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Vicryl Rapide™ (polyglactin 910)
Number of subjects: 250
Study: 25926562

Group type: EXPERIMENTAL
Intervention: Intra-myocardial injections of MSC
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 23096052

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 28

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 28
Study: 21763101

Group type: EXPERIMENTAL
Intervention: Intensive group cognitive therapy (IGCT)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Individual cognitive therapy (ICT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Intensive group cognitive therapy (IGCT) and Individual cognitive therapy (ICT)
Number of subjects: 67
Study: 19356906

Group type: EXPERIMENTAL
Intervention: BCAAs
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 16786421

Group type: EXPERIMENTAL
Intervention: EmbryoGlue treatment prior to embryo transfer
Number of subjects: 815

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 815
Study: 14557172

Group type: EXPERIMENTAL
Intervention: Oral acetylsalicylate
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Oral acetazolamide
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Ocular massage
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Isovolemic hemodilution
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Oral pentoxifylline
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Topical beta-blocker
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Paracentesis of the anterior chamber
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin
Number of subjects: 71
Study: 11197628

Group type: EXPERIMENTAL
Intervention: C5b-9 immunohistochemical marker
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: NP57 immunohistochemical marker
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: H&E staining
Number of subjects: 2
Study: 8639370

Group type: EXPERIMENTAL
Intervention: Smoking reduction advice in combination with dental health instruction and periodontal care
Number of subjects: 98

Group type: COMPARATOR
Intervention: Dental health instruction only (control)
Number of subjects: 98
Study: 1592361

Group type: EXPERIMENTAL
Intervention: idarubicin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: daunorubicin
Number of subjects: 16
Study: 6234335

Group type: EXPERIMENTAL
Intervention: Topical 4% erythromycin/1.2% zinc acetate solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle-control
Number of subjects: 0
Study: 31295391

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Laser (Er,Cr:YSGG laser device, Waterlase)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Hydrofluoric acid treatment [9.6% HF (Pulpdent) for 2 minutes]
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sandblasting (50 µm Al2O3)
Number of subjects: 160
Study: 29864437

Group type: EXPERIMENTAL
Intervention: Partial gland ablation with vascular targeted photodynamic therapy
Number of subjects: 413

Group type: COMPARATOR
Intervention: Active surveillance
Number of subjects: 413
Study: 25777270

Group type: EXPERIMENTAL
Intervention: Cognitive intervention (two weekly 1-hour therapy sessions)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Waitlist control (self-monitoring during a similar waitlist period)
Number of subjects: 24
Study: 25176361

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg orally one hour before surgery and then every 12 hours for the first 24 hours after surgery
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 120
Study: 22488231

Group type: COMPARATOR
Intervention: 65 g/L carbohydrate (trial C)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50 g/L carbohydrate and 15 g/L whey protein isolate (trial CP)
Number of subjects: 12
Study: 19930146

Group type: EXPERIMENTAL
Intervention: High-definition colonoscopy (HD)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Standard colonoscopy (SC)
Number of subjects: 390
Study: 17517858

Group type: EXPERIMENTAL
Intervention: Continuous grid‐based vigilance task during exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: No vigilance task during exercise
Number of subjects: 10
Study: 16124349

Group type: EXPERIMENTAL
Intervention: Pralidoxime (P2AM)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 12161513

Group type: EXPERIMENTAL
Intervention: Metyrapone treatment followed by hydrocortisone replacement in elderly subjects with moderate cortisol levels (n = 8)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment in elderly subjects with high cortisol levels (n = 9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Metyrapone treatment in elderly subjects with high cortisol levels (n = 9)
Number of subjects: 17
Study: 10561913

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study: 8558936

Group type: EXPERIMENTAL
Intervention: IL-3 at 5 microgram(s)/kg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: IL-3 at 7.5 microgram(s)/kg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: IL-3 at 10 microgram(s)/kg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: IL-3 (all doses combined)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Neutrophil recovery
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Platelet recovery
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adverse events during IL-3 and chemotherapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: IL-3 at 10 microgram(s)/kg
Number of subjects: 20
Study: 1686250

Group type: EXPERIMENTAL
Intervention: CCK-4 (25 μg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: CCK-4 (50 μg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: CCK-4
Number of subjects: 23
Study: 6341045

Group type: EXPERIMENTAL
Intervention: Cefaclor 500 mg three times daily for seven days
Number of subjects: 34

Group type: COMPARATOR
Intervention: Amoxicillin 750 mg three times daily for seven days
Number of subjects: 34
Study: 30453889

Group type: EXPERIMENTAL
Intervention: M1 (Mesangial hypercellularity)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: M0 (No mesangial hypercellularity)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: T1/2 (Tubulointerstitial fibrosis)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: T0 (No tubulointerstitial fibrosis)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: C1/2 (Glomerular crescents)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: E (Endocapillary hypercellularity)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: S (Glomerular segmental sclerosis)
Number of subjects: 162
Study: 28904319

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight chitosan solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nystatin suspension
Number of subjects: 40
Study: 26298053

Group type: EXPERIMENTAL
Intervention: Target depth of feedback (TDF) 5 cm
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Target depth of feedback (TDF) 6 cm
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Target depth of feedback (TDF) 7 cm
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Target depth of feedback (TDF) 5 cm (on second bed)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Target depth of feedback (TDF) 6 cm (on second bed)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Target depth of feedback (TDF) 7 cm (on second bed)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Duty cycle
Number of subjects: 19